Skip to main content
SpringerLink
Log in

The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

We have tried to find out if the combination of a xenogenized tumor cell vaccine and antitumor drugs is able to induce a synergistic increase in the antitumor therapeutic effect. The degree of increase in the LTD50 (50% lethal tumor dose) is expressed numerically, as a quantitative index designed to compare degrees of transplantation resistance to tumor cell challenge. A LTD50 was achieved by an intradermal (i. d.) immunization with xenogenized tumor cells when challenged with tumor cells implanted intraperitoneally 2 weeks after the immunization: this LTD50 value was 527 000 times higher than that of the non-immunized group. When we combined this type of immunization with appropriate doses of bleomycin (BLM) or cyclophosphamide (CY), which are able to augment antitumor immunity, the LTD50 was 723 000–1190 000 times higher than that of the non-immunized group. This increase in the LTD50 is definitely higher than that achieved by a single immunization with irradiated tumor cells (× 33 000) and combined with either BLM (× 93 000) or CY (×140 000). We also studied the therapeutic effect of a tumor cell vaccine combined with antitumor drugs BLM or CY in tumor-bearing rats. We observed a synergistic effect caused by BLM or CY after i. d. immunization with xenogenized tumor cells: this showed a significant increase when compared with the therapeutic effects obtained by chemotherapy alone (P <0.01). Nevertheless, there was no evidence that the above antitumor effects is superior to the effect achieved by irradiated tumor cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Askenase PW, Hayden BJ, Gershon RK (1975) Augmentation of delayed-type hypersensitivity by dose of cyclophosphamide which does not affect antibody response. J Exp Med 141: 697

    Google Scholar 

  2. Abdul Hamied TA, Turk JL (1987) Enhancement of interleukin-2 release in rats by treatment with bleomycin and adriamycin in vivo. Cancer Immunol Immunother 25: 245

    Google Scholar 

  3. Adler A, Gillon G, Lurie H, Shaham J, Loven D, Shachter Y, Shami A, Servadio C, Stein JA (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randamized study of hormono-immuno-versus hormonotherapy, preliminary report of immunological and clinical aspects. J Biol Response Mod 6: 610

    Google Scholar 

  4. Berd D, Mastrangelo J (1987) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 48: 1671

    Google Scholar 

  5. Berd D, Mastrangelo J (1987) Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 47: 3317

    Google Scholar 

  6. Berd D, Mastrangelo J (1988) Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6: 337

    Google Scholar 

  7. Gotohda E, Sendo F, Hosokawa M, Kodama T, Kobayashi H (1974) Combination of active and passive immunization and chemotherapy to transplantation of methylcholanthrene-induced tumor in WKA rats. Cancer Res 34: 1947

    Google Scholar 

  8. Hengst JCD, Mokyr MB, Dray S (1981) Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163

    Google Scholar 

  9. Hosokawa M, Sendo F, Gotohda E, Kobayashi H (1971) Combination of immunotherapy and chemotherapy to experimental tumors in rats. Gann 62: 57

    Google Scholar 

  10. Hosokawa M, Okayasu T, Ikeda K, Katoh H, Suzuki Y, Kobayashi H (1983) Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunized cells. Cancer Res 43: 2301

    Google Scholar 

  11. Kobayashi H (1982) Modification of tumor antigenicity in therapeutics: increase in immunologic foreigness of tumor cells in experimental model systems. In: Mihich E (ed) Immunological approaches to cancer therapeutics. John Wiley & Sons, New York, p 405

    Google Scholar 

  12. Kobayashi H (1983) Modification of tumor cell antigen. 13th International Cancer Congress: Part E. Cancer management Alan R. Liss, New York, p 305

    Google Scholar 

  13. Kobayashi H, Sendo F (1979) Immunogenicity of viable xenogenized tumor cells. Gann Monogr Cancer Res 23: 27

    Google Scholar 

  14. Kobayashi H, Kodama T, Shirai T, Kaji H, Hosokawa M, Sendo F, Saito H, Takeichi N (1969) Artificial regression of rat tumors infected with Friend virus (xenogenization). Hokkaido J Med Sci 44: 133

    Google Scholar 

  15. Kobayashi H, Sendo F, Shirai T, Kaji H, Kodama T, Saito H (1969) Modification in growth of transplantable rat tumors exposed to Friend virus. J Natl Cancer Inst 42: 419

    Google Scholar 

  16. Kobayashi H, Sendo F, Kaji H, Shirai T, Saito H, Takeichi N, Hosokawa M, Kodama T (1970) Inhibition of transplanted tumors by immunization with identical tumor cell infected with Friend virus. J Natl Cancer Inst 44: 11

    Google Scholar 

  17. Kobayashi H, Gotohda E, Hosokawa M, Kodama T (1975) Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor. J Natl Cancer Inst 54: 997

    Google Scholar 

  18. LaGrange PH, Mackaness GB, Miller TE (1974) Potentiation of T-cell mediated immunity by selective suppression of antibody formation with cyclophosphamide. J Exp Med 139: 1529

    Google Scholar 

  19. Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H (1985) Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res 45: 1502

    Google Scholar 

  20. Morikawa K, Hosokawa M, Hamada J, Xu ZY, Kobayashi H (1986) Possible participation of tumoricidal macrophages in the therapeutic effect of bleomycin on the transplantable rat fibrosarcoma. Cancer Res 46: 684

    Google Scholar 

  21. Naito K, Pellis NR, Kahan BD (1988) Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide and adoptive transfer of tumor-specific cytotoxic T-cell clones. Cell Immunol 111: 216

    Google Scholar 

  22. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J Exp Med 55: 1063

    Google Scholar 

  23. Okayasu T, Hosokawa M, Tanabe T, Kobayashi H (1986) The active immunotherapy of a 3-methylcholanthrene induced rat tumor with Friend virus-infected tumor cells. Jpn J Cancer Res (Gann) 77: 817

    Google Scholar 

  24. Parker D, Turk JL (1984) Potentiation of T-lymphocyte function by bleomycin. Immunopharmacology 7: 109

    Google Scholar 

  25. Polak LW, Turk JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249: 654

    Google Scholar 

  26. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493

    Google Scholar 

  27. Schultz RM, Pavlidis NA, Chiligos MA, Weiss JF (1978) Effects of whole body X-irradiation and cyclophosphamide treatment on induction of macrophage tumoricidal function in mice. Cell Immunol 38: 302

    Google Scholar 

  28. Terashima M, Takeichi N, Suzuki K, Itaya T, Gotohda E, Kobayashi H (1980) Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide. Tohoku J Exp Med 132: 355

    Google Scholar 

  29. XU ZY, Hosokawa M, Morikawa K, Kobayashi H (1986) Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin. Cancer Immunol Immunother 23: 46

    Google Scholar 

  30. Yamaguchi H, Moriuchi T, Hosokawa M, Kobayashi H (1982) Increased or decreased immunogenicity of tumor-associated antigen according to the amount of virus-associated antigen in rat tumor cells infected with Friend virus. Cancer Immunol Immunother 12: 119

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Pathology, Cancer Institute, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-Ku, 060, Sapporo, Japan

    Masuo Hosokawa, Futoshi Okada & Hiroshi Kobayashi

  2. Second Department of Surgery, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-Ku, 060, Sapporo, Japan

    Masashi Komatsumoto, Takeshi Okayasu & Tatsuzo Tanabe

Authors
  1. Masashi Komatsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masuo Hosokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Futoshi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Okayasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatsuzo Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Komatsumoto, M., Hosokawa, M., Okada, F. et al. The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs. Cancer Immunol Immunother 33, 279–284 (1991). https://doi.org/10.1007/BF01756591

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01756591

Key words

Search

Navigation